Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia.
TLDR
In this article, the therapeutic potential of m6A-modifiers in controlling haematological disorders, especially acute myeloid leukaemia (AML), was summarized.Abstract:
Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have been predominantly focused on DNA methylation, histone modifications, and chromatin remodelling. Epitranscriptomics is an emerging field that encompasses the study of RNA modifications that do not affect the RNA sequence but affect functionality via a series of RNA binding proteins called writer, reader and eraser. Several kinds of epi-RNA modifications are known, such as 6-methyladenosine (m6A), 5-methylcytidine (m5C), and 1-methyladenosine. M6A modification is the most studied and has large therapeutic implications. In this review, we have summarised the therapeutic potential of m6A-modifiers in controlling haematological disorders, especially acute myeloid leukaemia (AML). AML is a type of blood cancer affecting specific subsets of blood-forming hematopoietic stem/progenitor cells (HSPCs), which proliferate rapidly and acquire self-renewal capacities with impaired terminal cell-differentiation and apoptosis leading to abnormal accumulation of white blood cells, and thus, an alternative therapeutic approach is required urgently. Here, we have described how RNA m6A-modification machineries EEE (Editor/writer: Mettl3, Mettl14; Eraser/remover: FTO, ALKBH5, and Effector/reader: YTHDF-1/2) could be reformed into potential druggable candidates or as RNA-modifying drugs (RMD) to treat leukaemia. Moreover, we have shed light on the role of microRNAs and suppressors of cytokine signalling (SOCS/CISH) in increasing anti-tumour immunity towards leukaemia. We anticipate, our investigation will provide fundamental knowledge in nurturing the potential of RNA modifiers in discovering novel therapeutics or immunotherapeutic procedures.read more
Citations
More filters
Journal ArticleDOI
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer
TL;DR: Zhang et al. as discussed by the authors systematically summarized the latest research progress on METTL14 as a new biomarker for cancer diagnosis and its biological function in human tumors and discuss its potential clinical application.
Journal ArticleDOI
Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors
Francesca Rossi,Alessandra Di Paola,Elvira Pota,Maura Argenziano,Daniela Di Pinto,Maria Maddalena Marrapodi,Caterina Di Leva,Martina Di Martino,Chiara Tortora +8 more
TL;DR: In this paper, a review of the possible biological mechanisms involved in the development of inflamm-aging, focusing on immune system alteration, oxidative stress, cellular senescence, and therapeutic strategies is presented.
Journal ArticleDOI
The Role of N6-Methyladenosine in the Promotion of Hepatoblastoma: A Critical Review
TL;DR:
Journal ArticleDOI
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH.
Sunil Kumar,Parth Sarthi,Indra Mani,Muhammad Umer Ashraf,Myeong-Ho Kang,Vishal Kumar,Yong-Soo Bae +6 more
TL;DR: In this article, the authors proposed to improve the efficacy of ICB-therapy by co-targeting molecular checkpoints especially N6A-modification machineries which can be reformed into RNA modifying drugs (RMD).
Journal ArticleDOI
Interplay Between m6A RNA Methylation and Regulation of Metabolism in Cancer
TL;DR: It is hypothesized that m6A modification could dysregulate the expression of glucose, lipid, amino acid metabolism, and other metabolites or building blocks of cells by adaptation to the hypoxic tumor microenvironment, an increase in glycolysis, mitochondrial dysfunction, and abnormal expression of metabolic enzymes, metabolic receptors, transcription factors as well as oncogenic signaling pathways in both hematological malignancies and solid tumors.
References
More filters
Journal ArticleDOI
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Aviva C Krauss,Xin Gao,Liang Li,Michael L. Manning,Paresma Patel,Wentao Fu,Kumar G. Janoria,Gerlie Gieser,David A. Bateman,Donna Przepiorka,Yuan Li Shen,Stacy S. Shord,Christopher M. Sheth,Anamitro Banerjee,Jiang Liu,Kirsten B. Goldberg,Ann T. Farrell,Gideon M. Blumenthal,Richard Pazdur +18 more
TL;DR: Vyxeos is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC, and labeling includes a warning against interchanging formulations during treatment.
Journal ArticleDOI
MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.
Julian Musa,Marie-Ming Aynaud,Olivier Mirabeau,Olivier Delattre,Thomas G. P. Grunewald,Thomas G. P. Grunewald +5 more
TL;DR: MYBL2 and players of its downstream transcriptional network can be used as prognostic and/or predictive biomarkers as well as potential therapeutic targets to offer less toxic and more specific anti-cancer therapies in future.
Journal ArticleDOI
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Chao Shen,Yue Sheng,Allen C. Zhu,Sean Robinson,Xi Jiang,Xi Jiang,Lei Dong,Huiying Chen,Rui Su,Zhe Yin,Wei Li,Xiaolan Deng,Yinhuai Chen,Yinhuai Chen,Yueh-Chiang Hu,Yueh-Chiang Hu,Hengyou Weng,Huilin Huang,Emily Prince,Christopher R. Cogle,Miao Sun,Miao Sun,Bin Zhang,Chun-Wei Chen,Guido Marcucci,Chuan He,Zhijian Qian,Jianjun Chen +27 more
TL;DR: It is demonstrated that ALKBH5 is required for the development and maintenance of AML and self-renewal of leukemia stem/initiating cells (LSCs/LICs) but not essential for normal hematopoiesis, and the therapeutic potential of targeting the AL KBH5/m6A axis is highlighted.
Journal ArticleDOI
Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion
Zhenrui Li,Pengxu Qian,Pengxu Qian,Wanqing Shao,Hailing Shi,Xi C. He,Madelaine Gogol,Zulin Yu,Yongfu Wang,Meijie Qi,Yunfei Zhu,John M. Perry,Kai Zhang,Fang Tao,Kun Zhou,Kun Zhou,Deqing Hu,Deqing Hu,Yingli Han,Chongbei Zhao,Richard Alexander,Hanzhang Xu,Shiyuan Chen,Allison Peak,Kathyrn Hall,Michael Peterson,Anoja Perera,Jeffrey S. Haug,Tari Parmely,Hua Li,Bin Shen,Julia Zeitlinger,Chuan He,Chuan He,Linheng Li,Linheng Li +35 more
TL;DR: This study provides the first demonstration of the function of YTHDF2 in adult stem cell maintenance and identifies its important role in regulating HSC ex vivo expansion by regulating the stability of multiple mRNAs critical for HSC self-renewal, thus identifying potential for future clinical applications.
Journal ArticleDOI
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Danielle Golub,Nishanth Iyengar,Siddhant Dogra,Taylor Wong,Devin Bready,Karen Tang,Aram S. Modrek,Dimitris G. Placantonakis +7 more
TL;DR: The molecular pathways and oncogenic consequences associated with mut IDH with a particular emphasis on glioma and AML are summarized, and the development and preclinical testing of mutIDH inhibitors are systematically reviewed.
Related Papers (5)
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development
Chiou-Tsun Tsai,Chi Wai Eric So +1 more
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber,Junwei Shi,Junwei Shi,Eric Wang,Amy R. Rappaport,Amy R. Rappaport,Harald Herrmann,Edward Allan R. Sison,Daniel Magoon,Jun Qi,Katharina Blatt,Mark Wunderlich,Meredith J. Taylor,Christopher Johns,Agustin Chicas,James C. Mulloy,Scott C. Kogan,Patrick Brown,Peter Valent,James E. Bradner,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Christopher R. Vakoc +23 more